http://www.feedburner.comInstitute of Medicine RSS feed for the following topic: Quality and Patient SafetyCardiac arrest strikes almost 600,000 people each year, killing the vast majority of those individuals, says a new report from the Institute of Medicine.http://www.iom.edu/Reports/2015/Strategies-to-Improve-Cardiac-Arrest-Survival/Cardiac-Arrest-Survival-Report.aspx6/30/2015The Institute of Medicine conducted a study on the current status of, and future opportunities to improve, cardiac arrest treatment and outcomes in the United States. This report examines the complete system of response to cardiac arrest in the United States and identifies opportunities within existing and new treatments, strategies, and research that promise to improve survival and recovery of patients.http://www.iom.edu/Reports/2015/Strategies-to-Improve-Cardiac-Arrest-Survival.aspx6/30/2015Public release of the report of the Committee on Treatment of Cardiac Arrest will be held on June 30th, 2015 at 11:00 AM ET.http://www.iom.edu/Activities/PublicHealth/TreatmentofCardiacArrest/2015-June-30.aspx6/29/2015Tremendous variability in wait times for health care appointments exists throughout the U.S., ranging from same day service to several months, says a new report from the Institute of Medicine.http://www.iom.edu/Reports/2015/Transforming-Health-Care-Scheduling-and-Access/Getting-To-Now-Media-Advisory.aspx6/29/2015The Institute of Medicine (IOM) report Crossing the Quality Chasm identified six fundamental aims for health care—that it be safe, effective, patient-centered, efficient, equitable, and timely. Of these fundamental aims, timeliness is in some ways the least well studied and understood. How can timely care be ensured in various health care settings, and what are some of the reasons that care is sometimes not timely? The report presented here was developed by the IOM Committee on Optimizing Scheduling in Health Care to answer such questions. http://www.iom.edu/Reports/2015/Transforming-Health-Care-Scheduling-and-Access.aspx6/29/2015The first of a series of three workshops, this workshop will be aimed at advancing the understanding of effective approaches in managing the care of high-need patients, drawing attention to opportunities to improve outcomes and reduce the costs of health care for these vulnerable populations.http://www.iom.edu/Activities/Quality/VSRT/2015-JUL-07.aspx6/26/2015Military Trauma Care’s Learning Health System and its Translation to the Civilian Sector Committee Meeting #2http://www.iom.edu/Activities/HealthServices/LearningTraumaSystems/2015-JUL-23.aspx6/26/2015Biological differences between the sexes influence not only individual health but also public health, biomedical research, and health care. The IOM held a workshop March 8-9, 2010, to discuss sex differences and their implications for translational neuroscience research, which bridges the gap between scientific discovery and application.http://www.iom.edu/Reports/2010/Sex-Differences-and-Implications-for-Translational-Neuroscience-Research.aspx6/24/2015Millions of people in sub-Saharan Africa suffer from mental, neurological, and substance use (MNS) disorders, and most do not have the resources to obtain treatment. The Uganda National Academy of Sciences and the IOM hosted a workshop to discuss the state of care for MNS disorders in sub-Saharan Africa.http://www.iom.edu/Reports/2010/Mental-Neurological-and-Substance-Use-Disorders-in-Sub-Saharan-Africa-Reducing-the-Treatment-Gap-Increasing-Quality-of-Care.aspx6/24/2015Problems with how the neurotransmitter glutamate functions in the brain have been linked to a wide variety of disorders, including schizophrenia, Alzheimer’s, substance abuse, and traumatic brain injury. Efforts to understand, treat, and prevent glutamate-related disorders can be aided by the identification of valid biomarkers. The IOM’s Forum on Neuroscience and Nervous System Disorders held a workshop June 21-22, 2010, to explore ways to accelerate the development, validation, and implementation of such biomarkers.http://www.iom.edu/Reports/2011/Glutamate-Related-Biomarkers-in-Drug-Development-for-Disorders-of-the-Nervous-System.aspx6/24/2015The Food and Drug Administration (FDA) now requires that all clinical trials for drugs that affect the central nervous system—including psychiatric drugs—are assessed for whether that drug might cause suicidal ideation or behavior. The IOM’s Forum on Neuroscience and Nervous System Disorders hosted a meeting on June 26, 2009, to discuss the FDA’s new policy and how to analyze best whether suicidal thoughts predict actual suicidal behavior in the near future.http://www.iom.edu/Reports/2010/CNS-Clinical-Trials-Suicidality-and-Data-Collection.aspx6/24/2015Presentation at the Alzheimer's Association International Conference on Alzheimer's Disease 2011 http://www.iom.edu/Activities/Research/NeuroForum/2011-JUL-18.aspx6/24/2015The goal of the workshop was to present promising current and emerging technologies with potential as reliable glutamate biomarkers, and to outline strategies to accelerate development, validation, and implementation of these biomarkers as powerful tools to advance drug development for nervous system disorders associated with glutamatergic dysfunction.http://www.iom.edu/Activities/Research/NeuroForum/2010-JUN-21.aspx6/24/2015This IOM workshop will examine the clinical benefits and comparative effectiveness of emerging advanced technologies for cancer treatment in radiation therapy and surgery. Workshop participants will discuss current utilization patterns, with a focus on diffusion of new technologies into oncology practice, as well as evidence on the overuse, underuse, and misuse of these technologies, and potential strategies to assess the value and define optimal use of new technologies in cancer treatment.http://www.iom.edu/Activities/Disease/NCPF/2015-JUL-20.aspx6/23/2015On June 25, 2008, the IOM Forum on Neuroscience and Nervous System Disorders hosted more than 70 of the leading neuroscientists in the world, for a workshop titled From Molecules to Minds: Challenges for the 21st Century. The objective of the workshop was to explore a set of common goals or “Grand Challenges” posed by participants that could inspire and rally both the scientific community and the public to consider the possibilities for neuroscience in the 21st century.http://www.iom.edu/Reports/2008/From-Molecules-to-Minds-Challenges-for-the-21st-Century.aspx6/23/2015The mission of the Roundtable is to move forward the field of health literacy by translating research findings to practical strategies that can be implemented.http://www.iom.edu/Activities/PublicHealth/HealthLiteracy.aspx6/12/2015This workshop, hosted by the National Cancer Policy Forum, will examine the rationale and potential for integrating clinical trials for pets with naturally occurring cancers into translational cancer research and development. It will also highlight potential opportunities to overcome existing challenges.http://www.iom.edu/Activities/Disease/NCPF/2015-JUN-08.aspx6/10/2015Health Literacyhttp://www.iom.edu/Activities/PublicHealth/HealthLiteracy/2015-JUL-09.aspx6/8/2015The first workshop in a two-part series on cancer care in low resource areas. The first workshop will focus on cancer prevention and early detection.http://www.iom.edu/Activities/Disease/NCPF/2015-OCT-26.aspx6/5/2015The IOM Roundtable on Value & Science-Driven Health Care convenes leadership from key healthcare sectors to catalyze the collaborative work needed to drive improvements in the effectiveness and efficiency of medical care, by transforming how evidence is developed and used in health care.http://www.iom.edu/Activities/Quality/VSRT.aspx6/1/2015The IOM's Forum on Neuroscience and Nervous System Disorders focuses on building partnerships to further understand the brain and nervous system, disorders in their structure and function, as well as effective clinical prevention and treatment strategies.http://www.iom.edu/Activities/Research/NeuroForum.aspx5/27/2015More than 1.2 billion people worldwide play video games (online, via console, mobile phone, and other wireless devices), and many may be unaware that programmers often incorporate neuroscience into game design. Given the high prevalence of gaming in today’s society, the Institute of Medicine (IOM) Forum on Neuroscience and Nervous System Disorders hosted the Social Issues Roundtable at the Society for Neuroscience annual meeting on November 16, 2014, in Washington, DC, to explore the neuroscience of video games, with emphasis on relevant scientific, ethical,and societal issues.http://www.iom.edu/Reports/2015/Neuroscience-Gaming-WIB.aspx5/26/2015As the war in Afghanistan ends and as individuals leave the military, there is concern that experience and knowledge pertaining to advances gained from the wars may be lost within the military itself. Intentional steps to codify and garner the lessons within the military’s learning health system and promote their translation to the civilian sector are needed to ensure a ready military medical force for future combat operations. More systematic efforts to translate military advances in trauma care to the civilian community has the additional purpose of improving the response to multiple casualty events in the civilian setting such as mass shootings, stabbings and improvised explosive devices. In this context, the Institute of Medicine has convened an ad committee to ensure lessons learned from the military’s knowledge-generating research investment are sustained and built upon for future combat operations, and translated into the U.S. civilian health system.http://www.iom.edu/Activities/HealthServices/LearningTraumaSystems.aspx5/21/2015Military Trauma Care’s Learning Health System and its Translation to the Civilian Sector - Committee Meeting #1http://www.iom.edu/Activities/HealthServices/LearningTraumaSystems/2015-MAY-18.aspx5/20/2015At this meeting, participants will review tools, strategies, and priorities in the roles of clinicians, patients, and families in shared decision making for advanced illness and end-of-life circumstances; review progress and next steps related to stakeholder roles in transforming shared decision making into a routine element of patient care; and identify possible collaborative activities for ECIC participants to facilitate progress.http://www.iom.edu/Activities/Quality/VSRT/2015-JUN-05.aspx5/14/2015Through invited presentations and panel discussions, this workshop hosted by the NCPF and the American Cancer Society (ACS) will examine recent trends in comprehensive cancer care for pediatric cancer patients and their families and consider potential policy actions to improve care and outcomes. Participants will review existing evidence and efforts for integrating pediatric palliative care and quality of life strategies in childhood oncology research and practice, and will discuss additional research needed to minimize toxicities of pediatric cancer treatments and the resultant symptoms and late effects. A major goal of the workshop will be to facilitate discussion about potential strategies and actions for effectively applying existing evidence and quality of life strategies into pediatric oncology research, development, and practice. http://www.iom.edu/Activities/Disease/NCPF/2015-MAR-09.aspx5/14/2015The workshop, hosted by the NCPF and sponsored by the American Cancer Society, will review the state of the evidence regarding interpretive performance in mammography, identify remaining gaps, and consider potential opportunities for advancing research and practice.http://www.iom.edu/Activities/Disease/NCPF/2015-MAY-12.aspx5/13/2015A substantial body of evidence shows that broad improvements to end-of-life care are within reach. In Dying in America, a consensus report from the Institute of Medicine (IOM), a committee of experts finds that improving the quality and availability of medical and social services for patients and their families could not only enhance quality of life through the end of life, but may also contribute to a more sustainable care system.http://www.iom.edu/Reports/2014/Dying-In-America-Improving-Quality-and-Honoring-Individual-Preferences-Near-the-End-of-Life.aspx5/11/2015Clinical trials are a crucial part of the development process for new medical innovations. They are used to investigate the safety and efficacy of new therapeutics, medical devices, biologics, or procedures; determine the patient population where novel products will have the greatest positive effect; or provide detailed information on the therapeutic experience of individual patients. These trials represent a significant investment from all involved—patients who volunteer to participate, organizations that sponsor trials, and the researchers who conduct a study and analyze the data—with the resultant data being used to determine whether a medical product or procedure has the potential to improve the health of individuals.http://www.iom.edu/Activities/Research/SharingClinicalTrialData.aspx4/30/2015The IOM and the Committee on Core Metrics for Better Health at Lower Cost will release their report to the public on April 28, 2015 in Washington, DC.http://www.iom.edu/Activities/Quality/CoreMetricsForBetterHealth/2015-APR-28.aspx4/29/2015